Valeritas (NSDQ:VLRX) touted data today from a publication detailing the benefits of diabetes medication delivery devices, such as the company’s V-Go insulin delivery system. The article was published in the journal Managed Care.
The Bridgewater, N.J.-based company’s V-Go device is a wearable, basal-bolus insulin delivery system for patients with Type II diabetes. Patients can administer a continuous, preset basal rate of insulin over 24 hours, Valeritas said, with on-demand dosing at meals.
Get the full story at our sister site, Drug Delivery Business News.